2026-2032 年嬰幼兒營養低聚醣市場規模（按形式、應用、類型和地區）

嬰兒營養寡糖市場評估（2026-2032）

越來越多的家長開始青睞機能性食品不僅能提供基本營養，還能帶來其他健康益處。添加寡糖的嬰兒奶粉完美契合了這一新興趨勢，為嬰兒提供了量身定做的機能性食品選擇。因此，隨著機能性食品的普及，其市場規模預計將在2024年超過2.3565億美元，到2032年將達到4.0785億美元。

嬰兒奶粉製造商正逐步在其產品中加入寡醣，以模擬母乳的健康益處並提高奶粉的營養成分。這種新興模式滿足了那些希望用最接近母乳的替代品餵養嬰兒的父母的需求。因此，低聚醣在產品中的高滲透率將推動市場在2026年至2032年間以10.2%的複合年成長率成長。

嬰兒營養市場中的寡糖：定義/概述

寡糖是小分子碳水化合物，與澱粉等複合碳水化合物相比分子長度較短。寡糖是母乳中含量第三豐富的固態成分，僅次於脂肪和乳糖。寡糖是有益菌的重要食物來源，有助於培養嬰兒健康的腸道菌叢。越來越多的製造商將寡糖添加到其產品中，以複製母乳中的健康益處。其他寡糖包括人乳寡糖、三糖和半乳寡糖。

母乳寡糖可增加母乳哺育嬰兒大腸桿菌群中雙歧桿菌的數量。這種增加，加上潛在有害細菌數量的顯著減少，都歸因於寡糖的雙歧桿菌促生特性。母乳低聚醣不僅有助於母乳哺育嬰兒的腸道菌群，現在還能有效抑制細菌黏附在上皮表面。

未來，我們或許會發展出更接近母乳的新一代寡糖。隨著未來寡糖生產過程的日益精進，它們將更具成本效益，也更容易取得。嬰兒奶粉將根據每個嬰兒的特定需求，結合遺傳、腸道菌叢組成和過敏風險等因素，以客製化特殊的寡糖配方。

寡糖的多功能性如何推動其在嬰兒營養市場的成長？

寡糖的結構多樣性、豐富性和多功能性推動了嬰兒營養領域對寡糖的需求。寡糖是天然存在於母乳中的多功能聚醣。寡糖作為益生元，滋養腸道中的有益菌。寡糖作為有益菌的支持作用能夠促進腸道菌叢的和諧平衡，這對於高效消化和增強免疫功能至關重要。寡糖為有益菌提供了良好的環境，有助於腸道健康，並帶來多方面的益處，遠不止於消化功能。

寡糖作為益生元，促進腸道有益菌的生長，增強免疫系統。透過增強免疫系統，寡糖可以減少疾病，改善整體健康。寡糖可以減少過敏，在小鼠懷孕期間飼餵某些不可消化的寡糖，可以減輕其後代的過敏性氣喘症狀。

三糖與其他碳水化合物一樣，在體內分解成葡萄糖，葡萄糖是細胞能量的主要來源。三醣與單醣等單醣不同，它們的消化速度略慢，因此能量釋放更緩慢、更持續。不同的三糖在體內發揮不同的作用。例如，麥芽三糖是葡萄糖的三糖之一，它有助於肝醣儲存，這是人體在需要時儲存和釋放能量的機制。

雙醣是人體容易取得的能源來源。攝取後，它們會被消化酵素分解成單醣成分，這些單醣成分很容易在小腸中吸收，並分佈到全身各處的細胞。這種快速吸收能夠快速提供能量，支持各種身體功能。

家長意識的缺乏究竟阻礙了寡糖在嬰兒營養市場的成長嗎？

儘管目前已有研究，但某些寡糖對新生兒健康的長期影響尚不清楚。由於缺乏確鑿的長期數據，某些醫療保健提供者和家長可能不願意採用這些配方奶粉。並非所有家長都了解嬰兒奶粉中添加寡醣的益處。這種缺乏了解的情況，加上對某些化學物質的潛在誤解，可能會阻礙這些配方奶粉獲得廣泛的市場認可。

監管機構對嬰兒奶粉中可添加的寡糖種類和允許含量製定了標準。雖然嚴格的監管對於確保安全性和有效性至關重要，但它們可能會無意中扼殺創新和新型寡糖的市場推廣。因此，這種法律規範在確保產品安全和促進嬰兒營養進步之間難以取得平衡。

從嬰兒奶粉轉換為含寡糖配方奶粉的嬰兒可能會出現消化器官系統不適，例如腹脹和脹氣，尤其是在過渡不循序漸進的情況下。這一過渡期凸顯了謹慎引入強化寡糖配方奶粉的重要性，以避免潛在的不適。

配方奶粉中添加的寡糖雖然有用，但其結構與母乳中天然存在的寡糖不同。這種結構差異可能會導致一些人質疑配方奶粉和母乳的整體等效性。雖然添加寡糖可以改善配方奶粉的營養成分，但為了維護消費者的信心，識別並糾正這些可察覺的差異至關重要。

目錄

第1章 嬰幼兒營養寡糖全球市場介紹

• 市場概覽
• 研究範圍
• 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

• 資料探勘
• 驗證
• 第一手資料
• 資料來源列表

4. 嬰幼兒營養寡糖的全球市場展望

• 概述
• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 波特五力模型
• 價值鏈分析

5. 全球嬰幼兒營養寡糖市場（依型態）

• 概述
• 粉末
• 液體

6. 全球嬰幼兒營養寡糖市場（依應用）

• 概述
• 食物
• 健康食品
• 飲料
• 製藥

7. 全球嬰幼兒營養低聚醣市場（按類型）

• 概述
• 半乳寡糖
• 母乳寡糖
• 果寡糖

8. 全球嬰幼兒營養低聚醣市場（按地區）

• 概述
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區
  • 拉丁美洲
  • 中東

9. 全球嬰幼兒營養寡醣市場競爭格局

• 概述
• 各公司市場排名
• 主要發展策略

第10章 公司簡介

• Nissin Sugar Co. Ltd.
• Yakult Pharmaceutical Industry Co., Ltd.
• Kerry Group plc
• Taiwan Fructose
• Dupont nutrition & health
• Royal FrieslandCampina NV
• Abbot
• Ingredion
• Biosynth Carbosynth.
• Dextra Laboratories Ltd.
• Inbiose NV
• Jennewein Biotechnologie GmbH
• Tereos
• Zuchem

第10章 附錄

• 相關調查

Oligosaccharides in Infant Nutrition Market Valuation - 2026-2032

The growing inclination among parents towards functional foods, which go beyond providing basic nutrition by offering additional health benefits. Infant formula enriched with oligosaccharides perfectly fits into this emerging trend, presenting a functional food choice tailored specifically for infants. Thus, the increasing adoption of functional foods is driving market size to surpass USD 235.65 Million in 2024 to reach the valuation of USD 407.85 Million by 2032.

Manufacturers of infant formula are progressively integrating oligosaccharides into their products to emulate the health advantages of breast milk and elevate the nutritional content of their formulas. This emerging pattern addresses the needs of parents who aspire to offer their infants the most analogous substitute to breast milk available. Thus, the high enactment of oligosaccharides in products is enabling the market to grow at a CAGR of 10.2% from 2026 to 2032.

Oligosaccharide in Infant Nutrition Market: Definition/ Overview

Oligosaccharides are small carbohydrate molecules, shorter in length compared to complex carbohydrates such as starches. Oligosaccharides rank as the third most prevalent solid component in breast milk, following fats and lactose. They act as a vital food source for beneficial bacteria, fostering a healthy gut microbiome in infants. Manufacturers are increasingly incorporating oligosaccharides into their products to replicate the health advantages found in breast milk. In addition, there are types of oligosaccharides human milk oligosaccharide, trisaccharide, and Galactooligosaccharides.

The human milk oligosaccharides lead to a rise in the population of bifidobacteria in the colonic flora of breastfed infants. This increase is coupled with a notable decrease in the number of potentially harmful bacteria, attributed to the bifidogenic properties of oligosaccharides. Human milk oligosaccharides not only contribute to intestinal flora in breastfed infants but now oligosaccharides also serve as a potent inhibitor of bacterial adhesion to epithelial surfaces.

In the future, it is likely to develop a new generation of oligosaccharides that closely resemble breast milk. The advanced production of oligosaccharide in the future can make it cost-effective, and increase its accessibility. The emergence of personalized infant formula featuring specific blends of oligosaccharides tailored to individual baby's requirements, taking into account factors such as genetics, gut microbiome composition, and potential allergies.

How the Multifunctionality of Oligosaccharide is Driving the Growth of Oligosaccharide in the Infant Nutrition Market?

The structural diversity, quantity, and multifunctionality of oligosaccharides are driving the demand for oligosaccharides in human infant nutrition. Oligosaccharide is a prominent component in human milk it is a multifunctional glycan, which is naturally present in human milk. Oligosaccharides serve as prebiotics, which nourish the beneficial bacteria residing in the gut. This support of oligosaccharide support as a good bacteria fosters a harmonious balance within the gut microbiome, it is vital for efficient digestion and bolstered immune function. Oligosaccharides provide a favorable environment for beneficial microorganisms, they also contribute to gut health, offer multifaceted benefits, and extend beyond digestion.

Oligosaccharide promote the growth of beneficial gut bacteria, because of its prebiotic action and fortifies the immune system. Oligosaccharides reduce illness by bolstering the immune system and demonstrate to improve general health and well-being. Oligosaccharide reduces the allergy, during pregnancy in mice the specific nondigestible oligosaccharide led to reduced allergic asthma symptoms in the offspring.

Trisaccharides, akin to other carbohydrates, undergo breakdown into glucose within the body, serving as the primary fuel source for cellular energy. Trisaccharides, distinguished from simple sugars like monosaccharides, undergo digestion at a slightly slower pace, resulting in a more gradual and sustained release of energy. Specific trisaccharides fulfill distinct roles within the body. For instance, maltotriose, a glucose trisaccharide, contributes to glycogen storage, which constitutes the body's mechanism for storing and releasing energy as needed.

Disaccharides serve as an easily accessible energy source for the body. Upon ingestion, digestive enzymes break them down into their monosaccharide components, which are readily absorbed by the small intestine and distributed to cells throughout the body. This rapid absorption facilitates quick energy delivery to support a range of bodily functions.

How the Lack of Awareness among the Parents is Hampering the Growth of Oligosaccharides in the Infant Nutrition Market?

Despite current studies, the long-term effects of particular oligosaccharides on newborn health are not well understood. Certain healthcare providers or parents may be hesitant to adopt these formulae due to a lack of conclusive long-term data. Not all parents are aware of the benefits of oligosaccharides in infant formula. This lack of understanding, along with potential misconceptions about certain chemicals, could be a barrier to widespread market acceptance.

Regulatory bodies have created criteria for the permitted types and quantities of oligosaccharides in infant formula. While tight regulations are necessary to ensure safety and efficacy requirements, they can unintentionally stifle innovation and the introduction of novel oligosaccharides to the market. As a result, this regulatory framework strikes a difficult balance between guaranteeing product safety and promoting advances in baby nutrition.

Infants switching to oligosaccharide-containing formula may experience digestive discomfort such as bloating or gas, especially if the transition is not gradual. This transition period emphasizes the significance of introducing oligosaccharide-enriched formulas with caution to avoid potential discomfort.

Although helpful, oligosaccharides added to the formula differ structurally from those found naturally in breast milk. This structural distinction may lead some to question the overall equivalence of formula and breast milk. While oligosaccharide supplementation improves the formula nutritionally, it is critical to identify and rectify any perceived discrepancies to maintain customer trust.

Category-Wise Acumens

How the Increasing Consumer Awareness of Gut Health and the Rise in the Infant Population is Driving the Human Milk Oligosaccharide Segment Growth?

The human milk oligosaccharide segment is substantially growing in the oligosaccharide infant nutrition market and is expected to continue its growth throughout the forecast period. Rising consumer knowledge of the benefits of gut health, as well as increased demand for nutritional supplements, are important drivers driving the human milk oligosaccharide (HMO)) segment in the oligosaccharide infant nutrition market. HMOs, known for their antibacterial and prebiotic qualities, are set to become widespread in a variety of industries, including infant formulae, pharmaceuticals, and functional foods. Population growth, rising mortality rates, and a greater emphasis on health awareness are likely to drive the HMO business ahead.

In addition, the rise in the infant population is contributing to the growth of the human milk oligosaccharide segment. For instance, the current birth rate in 2024 is 17.299 births per 1000 people and 17.464 per 1000 people in 2023. The increasing birth rate is fueling the demand for human milk oligosaccharides. In the United States, the provisional number of births is 3,661,220 in 2022.

The rising prevalence of chronic illnesses such as gastrointestinal disorders, diabetes, high blood pressure, and rickets is driving up demand for functional foods and beverages, boosting growth in the human milk oligosaccharide market. In addition, the infant formula and baby food businesses are expected to grow significantly because of rising demand, increased HMO production, and regulatory approvals. Ongoing research is always revealing new health benefits related to certain HMO configurations. This ongoing research is expected to widen the potential applications of HMOs beyond newborn nutrition, accelerating market growth.

How the Health Benefits Associated with the Oligosaccharide is Fueling the Growth of the Food Segment in the Oligosaccharide in Infant Nutrition Market?

The food segment is significantly showing the growth in the oligosaccharide in the infant nutrition market. The wide range of health advantages associated with functional oligosaccharides is a major reason for their integration into dietary products. These advantages include immunological modulation, intestinal health promotion, enhanced stomach microbial activity, increased calcium absorption, and bone mineral density maintenance, particularly among adolescents.

Furthermore, functional oligosaccharides provide distinct physiological benefits such as being zero or low in calories while performing specific functions such as stimulating the proliferation of beneficial bacteria such as Bifidobacterium, enhancing the body's immune response, preventing dental caries and constipation, and even exhibiting potential anti-tumor properties.

Natural sources of oligosaccharides, such as fructooligosaccharides (FOS) found in fruits and vegetables like onions and bananas, provide an extra impetus for their use in food items. Although these natural oligosaccharides may be difficult for the human body to digest, they are valuable bioactive components that helpful bacteria such as Bifidobacterium can easily consume. This usage promotes a healthy and active gut microbiota, which protects against gastrointestinal illnesses.

How will the Rising Birth Rate in Asia Pacific Drive the Market?

Asia Pacific is substantially growing the oligosaccharide in the infant nutrition market thanks to the increasing awareness of the importance of early childhood nutrition, combined with a comprehension of the favorable function oligosaccharides play in newborn health. As parents grow more health-conscious, they are actively looking for infant feeding solutions that not only meet their fundamental nutritional requirements but also provide additional health benefits.

In response to this trend, there is a shift toward a more holistic approach to infant nutrition, in which parents prioritize products that provide comprehensive nutritional support, such as oligosaccharides, which promote overall health and well-being. This increased understanding emphasizes the significance of early nutritional changes in determining long-term health outcomes for infants.

The growing demand for functional foods in APAC reflects a larger trend toward preventative healthcare and wellness-oriented lifestyles. Parents are looking for child nutrition products that contain oligosaccharides, which they believe are important for immunological health, digestive function, and overall growth and development during infancy.

Healthcare professionals, government organizations, and industry stakeholders use educational campaigns and initiatives to raise awareness about the importance of early childhood nutrition and the benefits of oligosaccharides. By providing parents with knowledge and information, these initiatives help to meet the growing demand for oligosaccharide-enriched infant feeding products in the APAC market.

Competitive Landscape

The competitive landscape for oligosaccharides in infant nutrition is dynamic and evolving. Companies that can successfully navigate these trends through innovation, cost-effectiveness, strategic partnerships, and a focus on sustainability are likely to thrive in this growing market.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players

operating in the oligosaccharides in infant nutrition market include:

• Nissin Sugar Co. Ltd.
• Yakult Pharmaceutical Industry Co., Ltd.
• Kerry Group plc
• Taiwan Fructose
• Dupont nutrition & health
• Royal FrieslandCampina N.V.
• Abbot
• Ingredion
• Biosynth Carbosynth.
• Dextra Laboratories Ltd.
• Inbiose NV
• Jennewein Biotechnologie GmbH
• Tereos
• Zuchem

Key Devlopments

• In February 2019, DuPont Nutrition and Health announced an agreement with Lonza Specialty to manufacture and supply the CARE 4U-FL a Human Milk Oligosaccharide.
• In October 2023, Royal FrieslandCampina N.V. announced its entrance into the world's largest infant milk formula market in China.

Oligosaccharide in Infant Nutrition Market, By Category

• Form:
• Powder
• Liquid
• Application:
• Food
• Health Products
• Drinks
• Medicine
• Type:
• Galactooligosaccharides
• Human Milk Oligosaccharides
• Fructooligosaccharides
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET,

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY FORM

• 5.1 Overview
• 5.2 Powder
• 5.3 Liquid

6 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Food
• 6.3 Health Products
• 6.4 Drinks
• 6.5 Medicine

7 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY TYPE

• 7.1 Overview
• 7.2 Galactooligosaccharides
• 7.3 Human Milk Oligosaccharides
• 7.4 Fructooligosaccharides

8 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East

9 GLOBAL OLIGOSACCHARIDES IN INFANT NUTRITION MARKET, BY COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Nissin Sugar Co. Ltd.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Yakult Pharmaceutical Industry Co., Ltd.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Kerry Group plc
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Taiwan Fructose
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Dupont nutrition & health
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Royal FrieslandCampina N.V.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Abbot
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ingredion
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Biosynth Carbosynth.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Dextra Laboratories Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 Inbiose NV
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Jennewein Biotechnologie GmbH
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Tereos
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments
• 10.14 Zuchem
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook
  • 10.14.4 Key Developments

10 Appendix

• 10.1 Related Research